Trastuzumab: A Breast Cancer Drug Effective In Treating Advanced Gastric Cancer

Trastuzumab is a monoclonal antibody that has been significant in treating HER-2 breast cancers. Recently, it has been shown to prolong life in patients with a malignant epithelial condition. Since Trastuzumab also regulates angiogenesis and cancer signaling processes, it is likely to provide a significant benefit as an adjunct therapy (in combination with chemo). I like this approach because it is likely to greatly improve treatment for the 20% of gastric cancer patients that have HER-2 mutations. The following is a link to a gastric cancer clinical trials using Trastuzumab.
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC).

Speak Your Mind